Dual Vaccine Trial in Myeloproliferative Neoplasms

[Manouche]

Brief Summary:

A phase I-II study in patients with mutated MPN by vaccinating with PD-L1 and Aginase1 peptides with Montanide ISA-51 as adjuvant, to monitor the immunological response to vaccination and subsequently safety, toxicity and clinical effect.

Primary Purpose:Treatment

Official Title:Dual Vaccine Trial in Myeloproliferative Neoplasms

Estimated Study Completion Date :July 10, 2022

Primary Outcome Measures :

Immune response [ Time Frame: 1 year ]

T-cell cytokine release towards target antigens

Secondary Outcome Measures :

Adverse events evaluated by CTCAE v. 5.0 [ Time Frame: 1 year ]

Adverse events are graded 1-5 according to the criteria

Clinical response [ Time Frame: 10 year ]

Vaccinations will induce clinical response in 2 patients, either partial response or better, according response criteria for PV and ET or clinical response as a reduction of mutated allelic burden - 10% from baseline at any time.

clinicaltrials.gov/ct2/show...

[Bluetop]

Oh, a vaccine would be good!

[light]

Hi there, thank you for posting this info. Great news for us all. Wishing you well

[Aneliv9]

This could be therapeutical?

[Manouche in reply to Aneliv9]

The vaccine could be therapeutical. « the combination of vaccines with interferon-alpha (IFN-α) is a most interesting option. IFN-α is a potent immunostimulatory cytokine and has been used for years for the treatment of MPN. IFN-α has been shown to induce complete hematological responses and major molecular remissions in a substantial proportion of patients. Concurrently, treatment with IFN-α induces marked alterations in immune cell subsets and in the expression of HLA-related genes, and the mechanism beyond the clinical effet of IFN-α is believed to rely partially on the induction of an anti-tumor immune response. Previous reports on therapeutic cancer vaccination in other malignancies have underscored the importance of a low tumor burden at the time of vaccine initiation in order to obtain a proper clinical response. As IFN-α is the only drug, which is able to reduce the tumor burden in a substantial part of the patients, it is most apparent to reduce the tumor burden with IFN-α, and after attainment of a major molecular remission, initiate therapeutic cancer vaccination against the targets described above. This could hopefully eradicate the malignant clone and ultimately cure the patient.

frontiersin.org/articles/10...

[Aneliv9 in reply to Manouche]

I am.sorry to asking you again, i will read the whole study after this quick question! This vaccine is the same as the drug that is being injected?

[Aneliv9 in reply to Manouche]

This article is from 2018... Is there any progress?? Do you believe scientists still working on this vaccine? Or maybe is.an abandoned theory?

[Manouche in reply to Aneliv9]

Hi Aneliv,

As mentioned on the first article, the vaccine is being tested on a clinical trial finishing in July 2022.